511 related articles for article (PubMed ID: 33961133)
1. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Garla VV; Butler J; Lien LF
Curr Cardiol Rep; 2021 May; 23(6):59. PubMed ID: 33961133
[TBL] [Abstract][Full Text] [Related]
2. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
3. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R
Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310
[TBL] [Abstract][Full Text] [Related]
4. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
[TBL] [Abstract][Full Text] [Related]
5. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
7. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
Giaccari A; Pontremoli R; Perrone Filardi P
Int J Cardiol; 2022 Mar; 351():66-70. PubMed ID: 34979145
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
11. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Garla V; Subauste A; Butler J; Lien LF
J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
[TBL] [Abstract][Full Text] [Related]
13. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.
Ekanayake P; Hupfeld C; Mudaliar S
Curr Diab Rep; 2020 Nov; 20(12):74. PubMed ID: 33230620
[TBL] [Abstract][Full Text] [Related]
15. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
16. Current Perspectives of the Use of Sodium-Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney Disease.
Vider E; Sapir R; Mosseri E; Gavioli E
J Cardiovasc Pharmacol; 2022 Mar; 79(3):247-253. PubMed ID: 34775428
[TBL] [Abstract][Full Text] [Related]
17. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
18. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
20. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]